Axovant
Axovant attempts to rise from ashes with $842m Parkinson’s therapy deal
June 7, 2018Sales and Marketing Axovant, Oxford BioMedica, biotech, drugs, pharma, pharmaceutical
Axovant’s spectacular crash to Earth, after a soaring IPO that saw its share price hit the heady heights of $26, …
Axovant snatches Teva and Allergan execs to strengthen management
June 5, 2018Manufacturing and Production, Medical Communications Allergan, Axovant, Teva, appointment, pharma
Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr …
Axovant’s drug bested by placebo, shares reduced to dust
January 8, 2018Manufacturing and Production, Research and Development Axovant, Roivant, biotech, dementia, drugs, pharma, pharmaceutical
The signs were already there for Axovant Sciences’ key drug, intepirdine, when it posted poor results from a recent study …
Axovant shares capitulate after Alzheimer’s drug failure
September 26, 2017Research and Development Alzheimer's, Axovant, biotech, drugs, pharma, pharmaceutical
Axovant Sciences was set up with just one drug candidate in its portfolio, and a risky one, at that. The …
Latest content
